ASX ANNOUNCEMENT 7 August 2026 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Not for release to US wire services or distribution in the United States Share Purchase Plan – Now Open As...
Share Purchase Plan - Now Open
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Update - Proposed issue of securities - RAD
- Application for quotation of securities - RAD
- Quarterly Activities/Appendix 4C Cash Flow Report
- Change in substantial holding
- Target market determination (TMD)
Later from Radiopharm Theranostics
- Notice of Extraordinary General Meeting and Proxy Form
- RAD to meet with US FDA to align on RAD 101 Phase 3 Trial
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics